C4XD provides update on diabetes & inflammation compounds
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
List view / Grid view
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
22 September 2015 | By Victoria White
The companies have applied a crowdsourcing approach to establish a research team who will endeavour to identify new approaches for the treatment of patients with COPD...
15 July 2015 | By Victoria White
GSK and MRC are to collaborate on a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases...
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
30 April 2015 | By Victoria White
Scientists at Helmholtz Zentrum München have succeeded in testing the effectiveness of new approaches for treating COPD on ex vivo 3D-LTCs...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
12 June 2014 | By AstraZeneca
AstraZeneca announced a global licence agreement with Synairgen Plc for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma...